Press ReleasesHome / Who We Are / News / Press Releases Finding Solutions that Help a Unique Monoclonal Antibody Advance the Fight Against Metastatic Breast Cancer April 1, 2017 The Minneapolis Medical Research Foundation Selects Goodwin Biotechnology to Help Develop and Manufacture Two Vaccines to Treat Opioid Addiction March 20, 2017 Goodwin Biotechnology Expands its ADC Capabilities with a High Containment Suite for Development and cGMP Manufacturing of Cytotoxic ADCs May 17, 2016 IBC Generium Selects Goodwin Biotechnology to Optimize the Process, Scale‐Up, and Manufacture an IgG‐based Bispecific Antibody for Phase I Clinical Trials April 26, 2016 Goodwin Biotechnology Invests in Doubling its Space Available for cGMP Capacity as it Readies for Further Expansion of its Biopharmaceutical Manufacturing Business March 6, 2016 Goodwin Biotechnology Teams with Panacea Pharmaceuticals in Overcoming a Significant Bioconjugation Challenge for an Anti‐Cancer Monoclonal Antibody February 2, 2016 Goodwin Biotechnology Announces the Completion of cGMP Manufacturing of an IgM Monoclonal Antibody and IgM : Ligand Conjugate for Q Therapeutics, and Successful Clearance of Q Therapeutics’ IND Submission for Q‐Cells® Cell Therapy in ALS July 1, 2015 Goodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) Platform June 8, 2015 Goodwin Biotechnology was Selected by Panacea Pharmaceuticals for a Highly Specialized Vaccine Fill / Finish Project May 11, 2015 Goodwin Biotechnology Announces a Collaboration with Aspyrian Therapeutics for cGMP Manufacturing of an Innovative Antibody Drug Conjugate March 1, 2014Previous 1 2 3 4 5 Next